Introduction
============

Rotator-cuff tears (RCTs) caused by trauma are a common occurrence affecting millions of people worldwide. RCTs cause severe pain, which is exacerbated by arm movement and significantly reduces an individual's quality of life. In addition, the weakness caused by RCTs results in a major reduction in range of arm movement and arm strength, which also has a significant negative effect on an individual's quality of life, such as by making it difficult to dress oneself and to sleep. Therefore, it is essential to develop techniques that promote enhanced tendon repair and more reliable, significant, and long-lasting pain relief.

Causes of RCT pain
------------------

One cause of pain associated with RCTs is the development of inflammation, triggered in part by injury-induced platelet release of proinflammatory cytokines, such as IL1β, IL6, and TNFα.[@b1-jpr-11-2239],[@b2-jpr-11-2239] These cytokines also evoke persistent pathologic pain by directly activating nociceptive sensory neurons and causing nerve-injury-induced central sensitization.[@b3-jpr-11-2239],[@b4-jpr-11-2239] In addition, proinflammatory cytokines induce the upregulation of gene expression in nociceptive neuron axons and soma of voltage-gated sodium 1.8 ion channels, causing them to become chronically ectopically electrically active and thus sending continuous pain signals to the brain.[@b5-jpr-11-2239],[@b6-jpr-11-2239] Finally, inflammation and pain are triggered by lysed red blood cells at an injury site, releasing oxygen free radicals,[@b7-jpr-11-2239] with white blood cells releasing both oxygen free radicals and matrix metalloproteases.[@b8-jpr-11-2239]

These pain etiologies suggest that one approach to eliminating chronic pain associated with RCTs is to eliminate chronic inflammation. A technique for eliminating inflammation is to induce enhanced inflammation as a means of triggering the reinitiation of the normal wound-healing process, which involves an increasing level of inflammation that then decreases until it is completely eliminated. This can be accomplished by the application of PRP, which releases both pro- and anti-inflammatory cytokines. Alternatively, inflammation can be eliminated by the application of anti-inflammatory cytokines, such as IL1-receptor antagonist, IL10, IL11, and IL13.[@b2-jpr-11-2239] IL10 also reduces inflammation by blocking the synthesis and release of proinflammatory factors, upregulating the synthesis and release of additional anti-inflammatory cytokines and simultaneously downregulating the expression of genes for proinflammatory cytokine receptors.[@b4-jpr-11-2239] The efficacy of the administration of IL10 is shown by its suppressing the development of spinally mediated pain facilitation in various animal pain models, such as peripheral neuritis, spinal cord excitotoxic injury, and peripheral nerve injury.[@b9-jpr-11-2239] The end result of each approach is to induce the transition of a wound from a pro- to an anti-inflammatory state that does not evoke pain.

Another mechanism for eliminating inflammation-associated pain is the application of IL10, which is released by platelets and induces the downregulation of injury-induced gene expression for the voltage-gated sodium 1.8 ion channel in primary nociceptive neuron axons and somas.[@b5-jpr-11-2239],[@b6-jpr-11-2239],[@b10-jpr-11-2239] The loss of this ion channel results in the cessation of nociceptive neuron chronic ectopic electrical activity and thereby the loss of chronically evoked pain.

Techniques for promoting pain reduction following RCTs
------------------------------------------------------

### Corticosteroid injections

Due to their anti-inflammatory actions, corticosteroid injections are presently the method of choice to promote relief of pain associated with RCTs. However, there is the question of the reliability of corticosteroid injections to provide relief from pain due to RCTs, which have a success rate of 60%--100%.[@b11-jpr-11-2239]--[@b13-jpr-11-2239] Another limitation of cortisone use is that the level of pain reduction varies from 50% to 84%.[@b14-jpr-11-2239],[@b15-jpr-11-2239] Part of this variation may be due to lack of precision of the injury-site injection, with higher pain-suppression efficacy being obtained when using image-guidance tools for the injection, such as magnetic resonance imaging,[@b16-jpr-11-2239] dynamic fluoroscopic control,[@b17-jpr-11-2239] and ultrasound.[@b18-jpr-11-2239] Another limitation is that although cortisone's analgesic influence generally lasts 4--12 weeks[@b19-jpr-11-2239]--[@b22-jpr-11-2239] and may be effective for up to 6 months, its pain relief is generally not long-term.[@b13-jpr-11-2239],[@b23-jpr-11-2239],[@b24-jpr-11-2239] It is important to note that a repeat corticosteroid injection after 2 or 3 weeks does not increase the duration of the analgesic effects seen after 6 months.[@b11-jpr-11-2239]

### PRP injections

Numerous studies have tested the efficacy of injecting autologous platelet-rich plasma (PRP) into the site of RCTs to induce tendon healing and reduce chronic pain.[@b25-jpr-11-2239] The use of PRP for pain relief has two major limitations. First, a number of studies and analyses of the published literature have indicated a lack of reliable evidence that PRP provides effective pain relief.[@b26-jpr-11-2239]--[@b33-jpr-11-2239] In general, this conclusion is ascribed to the study samples being small, there being few controlled trials, and many results being anecdotal. However, a recent thorough meta-analysis of randomized controlled trials and a well-controlled study concluded that PRP improves rotator-cuff healing rates and functional outcomes and reduces pain levels.[@b34-jpr-11-2239],[@b35-jpr-11-2239] Several recent studies have also found that combining PRP with surgical tendon repairs significantly improves tendon healing while reducing retear rates, which should also contribute to pain reduction.[@b36-jpr-11-2239]--[@b38-jpr-11-2239] A second limitation is that when pain relief was observed, it was not long-lasting, generally lasting only 6 months,[@b21-jpr-11-2239],[@b29-jpr-11-2239],[@b39-jpr-11-2239]--[@b41-jpr-11-2239] although complete pain relief \>12 months has been reported.[@b42-jpr-11-2239],[@b43-jpr-11-2239]

Although results indicating that PRP provides pain relief are questioned, the failure of PRP to provide pain relief may result not from its inability to be effective, but from differences in the composition of the PRP applied in different studies. Such differences can arise due to the different devices used to separate PRP from whole blood. Different PRP-separation devices result in platelet concentrations that may be less than that of whole blood to sixfold as high, variations in pH,[@b44-jpr-11-2239] and differences in leukocyte and growth-factor concentrations that can vary by fivefold.[@b44-jpr-11-2239]--[@b47-jpr-11-2239]

Another significant factor influencing PRP composition is the physiological status of the person from whom blood is collected. As their physiological status changes, so does their blood composition, such as having an elevated leukocyte concentration. Elevated whole-blood leukocyte concentration can result in PRP with an elevated concentration of leukocytes. This is important, because leukocyte-rich PRP is detrimental to the proliferation of some stem/progenitor cells, leading to impaired tissue healing, because leukocytes inhibit the release of growth factors, such as VEGF, EGF, TGFβ~1~, and PDGF, increasing catabolic cytokine concentrations and causing inflammation and apoptosis.[@b47-jpr-11-2239]--[@b50-jpr-11-2239] Therefore, differences in PRP composition due to different PRP-separation devices or physiological changes in the patient may account for some of the variability in the efficacy of PRP on pain reduction.[@b51-jpr-11-2239],[@b52-jpr-11-2239]

Other factors may also alter the efficacy of PRP in inducing pain relief. While the optimal time to apply PRP in rats is immediately postinjury,[@b53-jpr-11-2239] it is not known if this is optimal for the clinical application of PRP. Although multiple PRP injections appear to promote pain reduction,[@b41-jpr-11-2239],[@b45-jpr-11-2239] there are no comparative data about the relative efficacy of one vs more PRP injections. All combined, these many variables can result in PRP having concentrations of factors that vary by more than 30-fold. Until it is known which factors and at what concentrations are critical for reducing inflammation and pain, each difference in PRP composition must be considered when evaluating whether PRP can or cannot reduce/ eliminate inflammation and pain. Finally, little is known about whether the efficacy of PRP can be increased if it is injected in combination with, prior to, or after, an injection of an anti-inflammatory mediator, such as a corticosteroid.

### Comparative influences of PRP and corticosteroids

The relative influences of PRP vs corticosteroid injections on pain relief vary in both the extent and duration of pain relief. While corticosteroid injections generally provide pain relief and the influence of PRP is more variable,[@b32-jpr-11-2239] corticosteroids may be more effective than autologous blood products in providing short-term (up to about 12 weeks) pain relief.[@b54-jpr-11-2239] For the intermediate term (6 months), autologous blood products appear to provide better therapeutic effect for pain relief than corticosteroids.[@b54-jpr-11-2239] However, for longer times, such as 6 months to 1 year, while there are reported to be no differences in the extent of reduction in pain levels,[@b55-jpr-11-2239],[@b56-jpr-11-2239] PRP has been reported to provide significantly greater pain relief.[@b52-jpr-11-2239],[@b57-jpr-11-2239] For pain relief due to osteoarthritis, corticosteroids are more effective than PRP, with higher corticosteroid doses inducing longer-lasting pain relief.[@b58-jpr-11-2239] However, PRP treatment has also been found to induce significantly more pain reduction for patients than is induced by corticosteroid injections,[@b59-jpr-11-2239] with the duration of PRP pain relief being significantly longer lasting than that of corticosteroids.[@b56-jpr-11-2239],[@b60-jpr-11-2239]--[@b62-jpr-11-2239] Therefore, in general, PRP induces a greater degree of longer-lasting pain relief than corticosteroids. However, the small samples and limited number of high-quality randomized controlled trials mean that further studies are required to validate these conclusions.

Pain development in injured shoulder followed by subsequent development of RCT and pain in contralateral shoulder
-----------------------------------------------------------------------------------------------------------------

Patients with a partial- or full-thickness RCT ipsilaterally to the trauma have a 36% risk of developing a full-thickness tear of the contralateral rotator cuff, with noticeable deficits in shoulder function related to daily living activities, even if the tear is asymptomatic.[@b63-jpr-11-2239]--[@b65-jpr-11-2239] The size of an RCT tear is an important factor in the development of increased symptoms. In contrast, patients with a partial-thickness tear or a normal rotator cuff on the painful side have rates of full-thickness tears that are low on the asymptomatic side of 4.3% and 0.5%, respectively.

Case report
===========

A 67-year-old male had a motor scooter accident causing him to fall to the ground, landing on his shoulder. Due to excruciating pain, the subject consumed ibuprofen (200 mg) and hydrocodone 7.5 (mg) up to six times per day as required. Although the subject had surgery to repair the damage scheduled, he wanted to try an alternative to surgery. As such, about 2.5 months following the accident, the subject received one injection of PRP into the right shoulder in the hope that the PRP would alleviate the pain and induce healing. By 7 days following the PRP injection, the subject's pain had decreased significantly, and by the end of the following 7 days he had stopped use of all analgesics. The scheduled surgery was canceled. After an additional 3 months, the patient had slight but annoying residual pain. The patient received a corticosteroid injection, and after 3 weeks was about 98% pain-free. The patient remained virtually pain-free more than 2 years and 2 months following the PRP injection.

About 7 months following the accident, the subject began to feel pain in the left shoulder contralaterally to the one that had caused the extreme pain. Although the pain was intense, it was not as severe as the pain of the first shoulder. Magnetic resonance imaging indicated that the pain was due to a partial tear of the left supraspinatus muscle. The pain was treated with ibuprofen 400 mg four times per day and hydrocodone 7.4 mg every day as needed, but the pain did not decrease with time.

After about 3 months of persistent pain, the patient received an injection of PRP into the second shoulder. By 1.5 months following the PRP injection, no pain relief had developed and the pain persisted at a relatively constant level for about another 5 weeks. Seeking pain relief, the subject received a corticosteroid injection into the shoulder, and within 12 days the pain had disappeared and the patient went off all analgesics. At 15 months following the corticosteroid injection, the second shoulder remained almost 100% pain-free. The subject still suffers some muscle weakness and there are some tasks, such as lifting heavy objects above his head, which he is unable to do. However, the patient considers the treatment a complete success. The patient provided written informed consent to have the case details published.

Discussion
==========

Many studies have reported success using PRP injections to reduce or eliminate chronic pain associated with RCTs and other tendon injuries.[@b21-jpr-11-2239],[@b39-jpr-11-2239]--[@b41-jpr-11-2239] However, systematic studies comparing the results of studies reporting the efficacy of PRP injection in providing pain relief have generally not found any statistical evidence supporting the claim that PRP is effective.[@b26-jpr-11-2239]--[@b28-jpr-11-2239],[@b31-jpr-11-2239]--[@b33-jpr-11-2239] These studies concluded that the major faults with studies claiming PRP efficacy in providing pain relief were their small samples and being uncontrolled. However, these comparative studies typically did not take into account factors that could significantly influence PRP efficacy.[@b44-jpr-11-2239],[@b45-jpr-11-2239],[@b47-jpr-11-2239],[@b51-jpr-11-2239],[@b52-jpr-11-2239] As such, the results from comparative studies should be considered valid only if they come from individuals on whom the same technique and device was used to prepare and administer the PRP,[@b16-jpr-11-2239]--[@b18-jpr-11-2239],[@b66-jpr-11-2239]--[@b68-jpr-11-2239] PRP was administered at the same time posttrauma, similar volumes of PRP were administered, PRP was applied to the same type of tissue, whether the physiological status of the patients was taken into account, and whether the study was clinical or on an animal model. Although these are rigorous requirements, only by comparing standardized studies will it be possible to determine whether PRP is truly effective. Comparing results from different standardized studies involving different sets of parameters should provide insights into which variables influence the potential efficacy of PRP on pain relief.

This paper discusses the results of a patient who developed excruciating chronic pain associated with RCTs in one shoulder and for whom the pain was virtually eliminated by an injection of PRP. The shoulder remained virtually 100% pain-free after 2 years and 2 months. At 7 months after the initial injury, severe chronic pain developed in the contralateral shoulder. An injection of PRP, prepared using the same technique as the first batch of PRP and administered by the same person, provided no pain relief. However, a subsequent injection of corticosteroid into that shoulder led to the elimination of the pain. That shoulder remained virtually 100% pain-free 17 months after the PRP injection and 15 months following the corticosteroid injection.

These results show that injections of PRP into the same patient, even when prepared using the same technique and administered by the same person, can result in complete or no pain elimination. This finding eliminates the potential that the differences in PRP influences were due to differences in how the PRP was prepared and administered. They suggest that the different outcomes resulted from injecting PRP with different PRP compositions are due to a change in the patient's physiological status, platelet count, and/or platelet factor content. These observations indicate that before reliable influences of PRP on pain relief can be anticipated, it is essential to determine the PRP composition required to eliminate chronic pain and the mechanisms by which pain is reduced/eliminated.

While tissue injury is associated with the development of inflammation and pain, the normal healing process leads to the reduction and eventual elimination of inflammation and its associated pain. However, for unknown reasons, injury sites can become stuck in a state of chronic inflammation, resulting in the generation of chronic pain. As mentioned, a number of mechanisms may eliminate chronic inflammation and its associated chronic pain, most of which involve the application of proinflammatory cytokines to trigger reinitiation of the wound-healing process, causing inflammation to increase followed by its elimination, anti-inflammatory cytokines to force the transition of a wound site directly from a pro- to an anti-inflammatory state, and an anti-inflammatory cytokine to eliminate spontaneous nociceptive neuron ectopic electrical activity.

When considering the potential efficacy of PRP and cytokines in providing pain relief, an important question is why when PRP appears to have the capacity to reduce pain, it does so inconsistently, and why when it is effective, its influence may be incomplete and not permanent. As suggested, the answer may lie in the variability of PRP composition such that it does not always induce the same degree or duration of inflammation suppression, and thus not the same degree of pain suppression. Variability in PRP composition may arise from different devices used to separate PRP from whole blood, yielding PRP with considerably different platelet concentrations, ratios of activated vs nonactivated platelets, pH, and concentration of platelet-contained factors. Each of these variables can greatly affect the capability of PRP to reduce inflammation and pain. Therefore, the composition of PRP-released factors may not be sufficient to trigger reinitiation of the pro- and anti-inflammatory process or entirely eliminate the proinflammatory state, which is required to eliminate inflammation permanently and thus pain.

Further complicating the reliability of the ability of PRP to reduce inflammation and pain is that the composition of PRP can vary greatly depending on inherent factors of the individual from whom PRP is prepared. These variables include the person's normal platelet count, heath status, such as illness or disease, levels of mental and physical stress, hormone levels, and drug and alcohol consumption. As such, the composition of PRP prepared from whole blood from the same individual using the same device can vary considerably over time. For the patient discussed in this paper, the composition of his PRP might have changed sufficiently between the first and second preparation of PRP, thus allowing it to eliminate the pain in his first shoulder completely, but failing to reduce pain when it was applied to the second shoulder.

Given these variables, the question remains about what might be done to eliminate chronic pain when PRP does not reduce or completely eliminate it. Is there an alternative approach that might be combined with the application of PRP to induce complete and permanent pain relief? Corticosteroid injections are generally considered effective in providing pain relief,[@b11-jpr-11-2239],[@b12-jpr-11-2239],[@b14-jpr-11-2239],[@b15-jpr-11-2239],[@b69-jpr-11-2239] although doubts remain as to their efficacy in reducing pain due to RCTs.[@b13-jpr-11-2239] Corticosteroids act to reduce inflammation and pain via multiple mechanisms. First, they markedly reduce production of the proinflammatory cytokines IFNγ, TNFα, IL1, and IL12.[@b1-jpr-11-2239] Second, similarly to platelets, corticosteroids suppress inflammation by increasing the synthesis and release of IL10,[@b70-jpr-11-2239] which leads to the upregulation of synthesis and release of additional anti-inflammatory cytokines.[@b4-jpr-11-2239] However, these actions do not always eliminate the proinflammatory environment entirely. Therefore, over time the residual inflammation may trigger renewed synthesis and release of proinflammatory cytokines, leading to a further increase in inflammation and increased pain. As such, a significant limitation of corticosteroids in providing pain relief appears to be their failure to suppress inflammation completely, resulting in the relatively short duration of their pain relief, generally not more than 6 months,[@b11-jpr-11-2239],[@b13-jpr-11-2239],[@b23-jpr-11-2239],[@b24-jpr-11-2239] and the reoccurrence of pain.

The present data raises the question of, why when PRP was injected into the second shoulder, it did not eliminate the pain, but a subsequent corticoid injection led to complete and long-lasting pain relief. Several possibilities could have acted singly or in combination. One is that the corticosteroid injection suppressed the synthesis and release of proinflammatory cytokines that had not been blocked or suppressed by the PRP injection. Corticosteroid promotion of the release of the anti-inflammatory cytokine IL10 could have reduced the proinflammatory state of the RCTs. Finally, corticosteroid-induced released IL10 may have suppressed the remaining spontaneous ectopic electrical activity of nociceptive neurons that was causing the chronic pain. Therefore, the combined action of PRP and the corticosteroid could have completely and permanently eliminated all inflammation, as well as spontaneous nociceptive ectopic electrical activity, leading to complete and permanent pain suppression. Further studies are required to determine whether when PRP fails or only partially reduces pain, reliable, complete, and long-lasting pain reduction can be induced by injection of a corticosteroid.

Conclusion
==========

This study found that an injection of PRP into the shoulder of an individual with RCTs causing severe chronic pain virtually eliminated the pain, while an injection of PRP 7 months later into the other shoulder that was also causing extreme pain had no impact on the pain level. However, for the second shoulder, a subsequent injection of corticosteroid led to the virtual elimination of the pain. The pain elimination for the two shoulders lasted more than 2 years and 2 months and 15 months respectively. These results indicate that even when the same device is used to prepare PRP and the PRP administered by the same individual using the same method, varying levels of pain reduction can result. This suggests that variations in a patient's physiological status may sufficiently alter their whole blood, leading to such a degree of change in the composition of their PRP that it is not effective in suppressing inflammation and pain. Because the pain relief provided by corticosteroids is normally short-lived, the complete and long-term pain relief achieved by the second shoulder when corticosteroid was administered following PRP suggests that this resulted from the combined actions of PRP and corticosteroids inducing a permanent transition of the RCT site from pro- to anti-inflammatory, which would lead to complete and permanent pain relief. Further studies are required to determine whether consistent, complete, and long-term pain relief is provided by combining an injection of PRP with corticosteroids, or by merely increasing the concentration of platelet-released factors.
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